Therapeutic Treatment for Benign Prostatic Hyperplasia

by Kirby; Roger S.

• ISBN13: 9781841846019
• ISBN10: 1841846015
• Format: Hardcover
• Copyright: 2005-07-12
• Publisher: CRC Press

Summary

The spectrum of treatment options for benign prostatic hyperplasia is matched by the spectrum of disease severity. New medications and minimally invasive modalities offer a greater range of choices to both the urologist and the patient. As BPH is rarely life-threatening, management is generally focussed on quality of life. With up to 90% of men in their 80s suffering from BPH to some extent, the prevalence of the disease is growing. It is imperative that patients be offered the full options available to manage BPH. Pharmacologic therapies available for the treatment of lower urinary tract symptoms secondary to BPH include alpha-adrenoceptor antagonists, such as terazosin, doxazosin, alfuzosin and tamsulosin, and the 5-alpha-reductase inhibitors, finasteride and dutasteride. Other strategies, such as plant-derived medication or watchful waiting, are applied to varying extents. This well-written and highly illustrated guide covers all these therapies and will well serve all urologists treating BPH.

Table of Contents

List of Contributors	vii
Medical management -- watchful waiting	1	(10)
P Hegarty
J M Fitzpatrick
R C Bruskewitz
The placebo effect in the treatment of benign prostatic hyperplasia	11	(30)
C G Roehrborn
Dutasteride in the treatment of the BPH patient	41	(12)
J D McConnell
C G Roehrborn
Finasteride in the treatment of benign prostatic hyperplasia	53	(14)
J D McConnell
Combination therapy in the treatment of BPH	67	(16)
C G Roehrborn
The differential effects of adrenoceptor antagonists on prostate tissue growth	83	(8)
N Kyprianou
Terazosin in the treatment of obstruction of the lower urinary tract	91	(12)
M K Brawer
J M Fitzpatrick
Doxazosin in the treatment of benign prostatic hyperplasia	103	(16)
R S Kirby
Alfuzosin	119	(20)
A Jardin
Tamsulosin	139	(28)
C R Chapple
Phytotherapeutic agents in the treatment of LUTS and BPH	167	(18)
K Dreikorn
J M Fitzpatrick
Uroselectivity revisited	185	(12)
K-E Andersson
M G Wyllie
Index	197